EU and US could reach trade deal this weekend - Reuters
Investing.com - Bruker Corporation (NASDAQ:BRKR), a scientific instruments manufacturer with a market capitalization of $5.4 billion, has pre-announced disappointing second-quarter results, with revenue expected to be $795-798 million, falling short of the $813 million consensus estimate. The stock is currently trading near its 52-week low of $34.10, having declined over 30% year-to-date.
The scientific instruments manufacturer reported an organic revenue decline of approximately 7% year-over-year, significantly worse than the anticipated 2% decline. Constant currency revenue decreased by approximately 3%, reflecting continued weakness in academic demand and softness in the U.S. biopharma market. According to InvestingPro data, despite current challenges, the company maintains a "GOOD" overall financial health score and analysts expect net income growth this year.
Non-GAAP earnings per share are projected to be in the $0.32-$0.34 range, substantially below the consensus estimate of $0.42. The company noted that the approximately $0.19 year-over-year EPS decline includes a $0.06 foreign exchange headwind.
Stifel has maintained its Hold rating on Bruker stock with a price target of $48.00. The investment firm highlighted that Bruker’s second-quarter organic revenue growth and adjusted EPS are tracking below the company’s current full-year guidance of 0%-2% growth and $2.40-$2.48 per share, respectively.
Bruker plans to address segment-level performance, margin details, and ongoing cost actions during its earnings call scheduled for August 4 at 8:30 a.m. EDT. Key focus areas will include order trends across academic and biopharma channels and potential revisions to the fiscal year 2025 outlook.
In other recent news, Bruker Corporation reported its preliminary second-quarter results, revealing flat reported revenue and a decline in adjusted earnings. The company estimated its revenue for the quarter ended June 30, 2025, to be between $795 million and $798 million, showing no growth compared to the same period last year. Bruker also noted a 7% year-over-year decline in adjusted organic revenue and a 3% decline when accounting for constant exchange rates. The company expects its adjusted earnings per share for the second quarter to be between $0.32 and $0.34, a decrease of approximately $0.19 per share from the previous year, partly due to a $0.06 impact from foreign currency fluctuations. These results were primarily affected by weak demand from academic institutions and softness in the U.S. biopharma market, which impacted the company’s bookings. A company executive highlighted the challenging market conditions, citing constraints in academic spending and a downturn in the biopharma sector as key factors. The recent developments have raised concerns among investors about Bruker’s short-term growth prospects amidst these market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.